Entrada Therapeutics, Inc. (TRDA) Stock

NASDAQ: TRDAFocuses on developing small molecule therapies for devastating diseases with high unmet medical needs.

Entrada Therapeutics stock price chart

TRDA interactive chart →

TRDA stock quote & key statistics

Entrada Therapeutics earnings per share

Income →

Earnings per share

Entrada Therapeutics revenue & net income

Income →

RevenueNet income

Entrada Therapeutics annual financials

Income statement →

Entrada Therapeutics, Inc. revenue, net income and EPS by fiscal year
Fiscal year	Revenue	Net income	EPS
FY2025	$25.4M	-$143.8M	-$3.46
FY2024	$210.8M	$65.6M	$1.91
FY2023	$129.0M	-$6.7M	-$0.26
FY2022	$25.3M	-$87.5M	-$3.02
FY2021	$0	-$50.1M	-$18.20

Fiscal year ending December 31. Source: company filings via EODHD.

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. is a pioneering biotechnology company focused on advancing therapies for a spectrum of neuromuscular diseases. Leveraging its innovative endosomal escape vehicle (EEV) platform, Entrada Therapeutics develops a diverse portfolio of therapeutic programs based on oligonucleotides, antibodies, and enzymes.

At the forefront of its pipeline, Entrada Therapeutics is advancing ENTR-601-44, its lead product candidate currently in preclinical trials for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. The company also develops EEV-PMO-CAG specifically targeting myotonic dystrophy type 1, underscoring its commitment to addressing unmet medical needs in neuromuscular disorders.

Formerly known as CycloPorters, Inc., Entrada Therapeutics rebranded in October 2017 to reflect its expanded focus and innovative approach to therapeutic development. Since its inception in 2016, the company has been headquartered in Boston, Masachusetts, strategically positioning itself within a vibrant biotechnology hub.

With a dedicated team and a robust pipeline, Entrada Therapeutics is poised to make significant strides in the treatment landscape of neuromuscular diseases. Through its pioneering EEV platform, the company aims to deliver transformative therapies that enhance the lives of patients worldwide.

Entrada Therapeutics stock FAQ

What is the Entrada Therapeutics stock ticker symbol?

Entrada Therapeutics, Inc. trades on the NASDAQ under the ticker symbol TRDA.

What sector and industry is Entrada Therapeutics in?

Entrada Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Entrada Therapeutics have?

Entrada Therapeutics, Inc. has about 152 full-time employees.

What were Entrada Therapeutics's revenue and earnings last fiscal year?

Entrada Therapeutics reported revenue of $25.4M and net income of -$143.8M in fiscal 2025, with earnings per share of -$3.46. Revenue declined 87.9% from the prior year.

Is Entrada Therapeutics in the Russell 2000?

Yes. Entrada Therapeutics, Inc. (TRDA) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Entrada Therapeutics go public?

Entrada Therapeutics stock began trading on October 29, 2021.

Russell 2000 Biotechnology stocks

All Russell 2000 →